Cases

PRECEDENTIAL UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT ____________ No. 24-2510 ____________ NOVO NORDISK INC.; NOVO NORDISK PHARMA, INC., Appellants v. SECRETARY UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; ADMINISTRATOR CENTERS FOR

DYK, Circuit Judge, dissenting. In 2003, Congress enacted the counterclaim provision of the Hatch-Waxman Act in order to prevent manipulative practices by patent holders with respect to the Orange Book listings. These practices were designed to delay the onset of competition from generic drug manufacturers. See Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub.L. No. 108-173,

Case: 24-1965 Document: 76 Page: 1 Filed: 01/29/2025 United States Court of Appeals for the Federal Circuit ______________________ REGENERON PHARMACEUTICALS, INC., Plaintiff-Appellee v. MYLAN PHARMACEUTICALS INC., AMGEN USA, INC., BIOCON BIOLOGICS INC., CELLTRION, INC., FORMYCON AG, AMGEN INC., Defendants SAMSUNG BIOEPIS CO., LTD., Defendant-A

United States Court of Appeals For the Eighth Circuit ___________________________ No. 22-1613 ___________________________ Larry Johnson Plaintiff - Appellant v. Schulte Hospitality Group, Inc. Defendant -

United States Court of Appeals for the Federal Circuit ______________________ ACORDA THERAPEUTICS INC., ALKERMES PHARMA IRELAND LIMITED, Plaintiffs-Appellees v. MYLAN PHARMACEUTICALS INC., MYLAN INC., Defendants-Appellants ______________________ 2015-1456 ______________________ Appeal from the United States District Court for th

Case: 21-2106 Document: 79 Page: 1 Filed: 07/13/2022 United States Court of Appeals for the Federal Circuit ______________________ KONINKLIJKE PHILIPS N.V., Plaintiff-Counter Defendant-Appellee PHILIPS RS NORTH AMERICA LLC, Counter Defendant-Appellee v. THALES DIS AIS USA LLC, FKA GEMALTO IOT LLC, FKA CINTERION WIRELESS MODULES NAFTA LLC, Defe

OPINION STARK, U.S. District Judge: Defendants Mylan Pharmaceuticals Inc. (“Mylan Pharma”) and Mylan Inc. (“Mylan Inc.” and, together with Mylan Pharmaceuticals, “Mylan” or “Defendants”) have moved to dismiss the complaint filed against them by Plaintiffs Acorda Therapeutics, Inc. (“Acorda”) and Alkermes Pharma Ireland Limited (“Alkermes” and, together with Acorda, “Plaintiffs”). (D.I.10) Defenda

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE SYMBIONT.IO, INC., ) ) Plaintiff, ) ) v. ) C.A. No. 2019-0407-JTL ) IPREO HOLDINGS, LLC, IPREO LTS LLC, ) IHS MARKIT LTD., and MARKIT NORTH ) AMERICA, INC., )

Case: 23-2254 Document: 118 Page: 1 Filed: 03/13/2025 United States Court of Appeals for the Federal Circuit ______________________ MERCK SHARP & DOHME B.V., MERCK SHARP & DOHME, LLC, Plaintiffs-Appellees v. AUROBINDO PHARMA USA, INC., AUROBINDO PHARMA LTD., USV PRIVATE LIMITED, GLAND PHARMA LIMITED, MANKIND PHARMA LTD., LIFESTAR PHARMA LLC, FRESENIUS KABI USA, LLC, DR. REDDY'S L

In the United States Court of Federal Claims No. 21-2323C Filed: August 31, 2022 Reissued for Publication: September 18, 20221 * * * * * * * * * * * * * * * * ** * GOODWILL INDUSTRIES OF SOUTH * FLORIDA, INC., * Protestor, * v. *

OPINION Hon. David T. Thuma, United States Bankruptcy Judge Before the Court is Defendants’ joint motion to dismiss this § 510(b)1 subordination proceeding for lack of standing. The Court concludes that the Plaintiff did not have standing to bring the action in the first instance, and further concludes that the plan confirmed in this case gave the reorganized debtor the sole ri

MEMORANDUM OPINION AND ORDER RODNEY GILSTRAP, UNITED STATES DISTRICT JUDGE Before the Court are the competing motions for summary judgment by Plaintiff Allergan Sales, LLC (“Allergan”) and Defendants Sandoz, Inc., Aleon Laboratories, Inc., Alcon Research, Ltd., and Falcon Pharmaceuticals, Ltd. (collectively “San-doz”) (Dkt. No. 277; Dkt. No. 280; Dkt. No. 281). Allergan’s motion sought summary judgment th

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE VINTAGE RODEO PARENT, LLC, a Delaware ) limited liability company, VINTAGE RODEO ) ) ACQUISITION, INC., a Delaware corporation, and VINTAGE CAPITAL MANAGEMENT, ) LLC, a Delaware limited liability company, ) ) Plaintiffs, ) ) and

OPINION OF THE COURT AMBRO, Circuit Judge. This case involves competing rights over the pharmaceutical paroxetine hydrochloride controlled release tablets (“paroxetine”) in generic form. Defendant/Appellee GSK 1 holds patent and FDA rights to market and sell paroxetine for the treatment of depress

Partial Summary Judgment; National Parks Service Concessions Contract; Valuation of Concessioner’s Possesso-ry Interest; Leasehold Surrender Interest; Statutory Interpretation; Contract Interpretation; Implied-in-Fact Contract. OPINION HORN, J. FINDINGS OF FACT and STATUTORY FRAMEWORK Plaintiff, Seven Resorts, Inc. (Seven Resorts), asserts a claim for compensation a

ORDER DENYING THE MYLAN DEFENDANTS’ MOTION TO DISMISS FOR LACK OF PERSONAL JURISDICTION SARAH EVANS BARKER, District Judge. This cause is before the Court on the Motion to Dismiss [Docket No. 150], filed on May 2, 2014, by Defendants Mylan Pharmaceuticals, Inc., Mylan, Inc., and Mylan Laboratories, Ltd. (collectively, “the Mylan Defendants”).1 The Mylan Defendants contend that we

LINN, Circuit Judge. In this Hatch-Waxman' Act litigation, Exela PharmSci Inc., Exela Holdings, Inc. and Exela Pharm' Sciences, LLC (collectively “Exela”) appéal the district court’s construction of certain claim terms of U.S. Patents No. 6,028,222 (the “'222 patent”) and No. 6,992,218 (the “'218 patent”), Cadence Pharm,., Inc. v. Paddock Labs. Inc., 886 F.Su

UNDER SEAL MEMORANDUM OPINION KETANJI BROWN JACKSON, United States District Judge Table Of Contents I.BACKGROUND ... 69 A. Colchicine: A Drug For The Treatment Of Gout ... 69 B. FDA’s Drug Approval Framework: The Hatch-Waxman Amendments ... 71 1. NDAs, ANDAs, and 505(b)(2) NDAs ...71

OPINION AND ORDER WOLSKI, Judge. This matter originally came before the Court as plaintiff MORI Associates’ protest of procurement actions taken by an agency of the United States Department of Health and Human Services. Plaintiff was challenging corrective action proposed by the government in response to a series of protests MORI brought before the Government Accountability Office, and challeng

MEMORANDUM OPINION SUE L. ROBINSON, District Judge. I. INTRODUCTION On January 14, 2011, plaintiff ButamaxTM Advanced Biofuels LLC (“Butamax”) filed suit in this district against defendant Gevo, Inc. (“Gevo”) alleging infringement of U.S. Patent No. 7,851,188 (“the '188 patent”). (D.I. 1) The '188 patent discloses and claims “a recombinant microorganism having an engineered isobutanol